History
A list of downloadable documents created during development.
Background information
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - GE decision paper - January 2015
-
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - provisional matrix of stakeholders
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix B - proposal paper presented to the Institutes Guidance Executive
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment - guidance development
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment - guidance development
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination document
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: consultee and commentator comments on the ACD
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche (PDF 499 KB)
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Pathologists
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Department of Health
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NHS Birmingham East and North
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Commissioning Support Appraisal Service
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: addendum by Liverpool Research Implementation Group (LRiG)
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: comments on the ACD received from the public through the NICE website
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation 2
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation 2
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: consultee and commentator comments on the ACD
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche Products
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: British Association of Dermatologists
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Department of Health
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Commissioning Support Appraisals Service
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Lorigan
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Lorigan (PDF 36 KB)
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: comments on the ACD received from the public through the NICE website
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appraisal consultation
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: evaluation report
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: pre-meeting briefing
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report
-
-
-
-
-
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Evidence Review Group report - factual accuracy check
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: manufacturer submission
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Roche Products
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: PAS submission from Roche Products
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: PAS submission from Roche Products
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: PAS proposal from Roche Products
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: clarification
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NICE request to the manufacturer for clarification on their submission - 1
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: manufacturer's response to NICE's request for clarification - 1
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: NICE request to the manufacturer for clarification on their submission - 2
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: manufacturer's response to NICE's request for clarification - 2
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: patient group, professional group and NHS organisation submission statements
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: British Association of Skin Cancer Nurse Specialists
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Nursing
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
-
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: expert written personal statements
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Chalk
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Chalk (PDF 300 KB)
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Fearfield
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Fearfield (PDF 69 KB)
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Gore
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Gore (PDF 328 KB)
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Lorigan
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Lorigan (PDF 293 KB)
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Nuttall
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Nuttall (PDF 95 KB)
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - final scope
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - final scope
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - draft scope for consultation (pre-referral) May 2011
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix B - draft scope for consultation (pre-referral) May 2011
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - final matrix
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - final matrix
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - provisional matrix (pre-referral) May 2011
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix C - provisional matrix (pre-referral) May 2011
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix D - NICE's response to consultee and commentator comments on the draft scope and matrix
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: appendix D - NICE's response to consultee and commentator comments on the draft scope and matrix
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: equality impact assessment
-